3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Melanoma
2
Colorectal Neoplasms
2
Advanced Solid Tumors
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor, Unspecified, Adult
1
Prostatic Neoplasms, Castration-Resistant
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Merkel Cell
1
Breast Neoplasms
1
Interventions
Rituximab
205
Cyclophosphamide
178
Peripheral Blood Stem Cell Transplantation
93
Etoposide
91
fludarabine phosphate
86
Filgrastim
81
Melphalan
62
Vincristine
60
Mycophenolic Acid
58
Busulfan
58
Whole-Body Irradiation
57
Cytarabine
51
Radiotherapy
49
Doxorubicin
49
Cyclosporine
49
Tacrolimus
48
Granulocyte Colony-Stimulating Factor
48
Prednisone
46
fludarabine
45
Bendamustine Hydrochloride
45
Methotrexate
44
Carmustine
36
Antilymphocyte Serum
34
Dexamethasone
32
Bortezomib
29
Gemcitabine
27
ibritumomab tiuxetan
25
Methylprednisolone
23
sargramostim
22
Stem Cell Transplantation
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, Non-Hodgkin
×
zimberelimab
×
Clear all
NCT04772989
2025-08-28
ARC-12
Arcus Biosciences, Inc.
Phase 1
Completed
94 enrolled